Cognition Therapeutics Inc.

89 articles with Cognition Therapeutics Inc.

• UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

  3/16/2023

  Cognition Therapeutics, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the market open.

• Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 ResultsConference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ET

  3/16/2023

  Cognition Therapeutics, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the market open.

• Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

  3/15/2023

  Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that its Investigational New Drug (IND) application for the investigation of CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) has been cleared by the U.S. Food and Drug Administration (FDA).

• Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference

  3/7/2023

  Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s president and CEO, Lisa Ricciardi will present at the annual Oppenheimer & Co Healthcare Conference taking place in a virtual format from March 13-15, 2023.

• Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

  2/22/2023

  Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S. Food and Drug Administration comment period and may now proceed with the 540-patient Phase 2 START study of CT1812 in adults with mild cognitive impairment or early Alzheimer’s disease.

• Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia

  2/21/2023

  Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its third “Conversations” video podcast, featuring a discussion with two Lewy body dementia caregivers, who are also passionate advocates for the second most common and devastating form of dementia.

• Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s DiseaseInnovative Trial Explores Theta Wave qEEG as a Biomarker of Synaptic Dysfunction

  2/9/2023

  Cognition Therapeutics, Inc. (Nasdaq: CGTX) today announced that enrollment has completed in the randomized, double-blind Phase 2 SEQUEL study (COG0202, NCT04735536) of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease.

• Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease

  12/22/2022

  Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released the second “Conversations” video podcast, featuring a virtual fireside discussion with neuroscience experts who share their perspective on clinical data recently presented at the 2022 CTAD conference in San Francisco, and implications for future Alzheimer’s disease,

• Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"

  12/21/2022

  Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s management team will participate in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase and BIO Partnering @ JPM. All events will be held in-person and are scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2023.

• First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812SHINE Study Expanded from USA to Include sites in Spain, the Netherlands, and Czech Republic

  12/15/2022

  Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced that the Phase 2 SHINE clinical trial of CT1812, an experimental oral, once-daily capsule in development for mild-to-moderate Alzheimer’s disease, has been expanded into clinical sites in Spain, the Netherlands, and the Czech Republic.

• Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

  12/1/2022

  Cognition Therapeutics, Inc. today announced that the scientific rationale, supporting proof-of-concept data and design of the planned Phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) will be communicated in an oral presentation at the 2022 Dry AMD Therapeutic Development Summit.

• Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

  11/28/2022

  Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the rationale and design of the Company’s ongoing SHIMMER clinical trial of CT1812 will be presented at the 2022 Clinical Trials in Alzheimer’s Disease (CTAD) conference.

• Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series

  11/21/2022

  Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has introduced a new podcast/webinar series named “Conversations,” that will feature virtual fireside chats with neuroscience experts to discuss advances in the research and treatment of Alzheimer’s disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions.

• Cognition Therapeutics Announces Closing of Public Offering

  11/15/2022

  Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $1.20 per share.

• Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/14/2022

  Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the “Company” or “Cognition”) today reported financial results for the third quarter ended September 30, 2022 and provided an update on the company’s business and clinical development progress.

• Cognition Therapeutics Announces Pricing of Public Offering - November 10, 2022

  11/10/2022

  Cognition Therapeutics, Inc., announced the pricing of the public offering of 5,000,000 shares of its common stock, at a public offering price of $1.20 per share, for gross proceeds of approximately $6.0 million, before deducting underwriting discounts and commissions and offering-related expenses.

• Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

  10/12/2022

  Lewy Body Dementia patients are actively being recruited by Cognition Therapeutics, Inc. and its clinical partners for the SHIMMER Phase 2 trial of their CT1812 oral drug therapy at 17 study sites across the country with more expected to open.

• Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

  10/11/2022

  Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development.

• Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference

  9/29/2022

  Cognition Therapeutics, Inc. announced today that the Company’s president and CEO, Lisa Ricciardi will participate in a panel discussion and host one-on-one meetings at the Cantor Fitzgerald Neurology & Psychiatry Conference taking place in San Francisco from October 6-7, 2022.

• Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

  9/27/2022

  Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease.